The significant change for the timed 25-foot walk in the multiple sclerosis functional composite

被引:42
作者
Kaufman, M
Moyer, D
Norton, J
机构
[1] MS Ctr Carolinas Hlthcare Syst, Charlotte, NC 28204 USA
[2] Carolinas Med Ctr, Carolinas Healthcare Syst, Dept Biostat, Charlotte, NC 28203 USA
来源
MULTIPLE SCLEROSIS | 2000年 / 6卷 / 04期
关键词
timed-walk; T25FW; exacerbation;
D O I
10.1191/135245800678827860
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The Timed 25-Foot Walk is under evaluation as a clinical tool to follow Patients with MS. Several approaches have been token to define a clinically significant change in this measurement This study was undertaken to define the range of values expected for the Timed 25-Foot Walk and to correlate prospectively the change in walk-time that occurs during on exacerbation of MS associated with subjective difficulty walking Five results from this study ore emphasized. (1) Patients who were minimally affected by MS frequently walked 25 feet between three and five seconds. (2) the walk-time variability, defined of the ratio of the longest to the shortest walk-time, minus 1, times 100% for three consecutive trials was generally 20% or less; (3) if the two fastest walk-times obtained in three trials were compared, the walk-time variability was almost always 10% or less; (4) for clinically stable individuals, the walk-times of single trials separated by 12 months or less generally varied less than 20%; and (5) patients who complained of difficulty walking but who did not hove changes otherwise detectable by examination, generally had a prolongation of walk-time. These results suggest that on increase of more than 20% in the Timed 25-Foot Walk may indicate a significant change in gait.
引用
收藏
页码:286 / 290
页数:5
相关论文
共 6 条
[1]   Intrarater and interrater reliability of the MS functional composite outcome measure [J].
Cohen, JA ;
Fischer, JS ;
Bolibrush, DM ;
Jak, AJ ;
Kniker, JE ;
Mertz, LA ;
Skaramagas, TT ;
Cutter, GR .
NEUROLOGY, 2000, 54 (04) :802-806
[2]   Development of a multiple sclerosis functional composite as a clinical trial outcome measure [J].
Cutter, GR ;
Baier, ML ;
Rudick, RA ;
Cookfair, DL ;
Fischer, JS ;
Petkau, J ;
Syndulko, K ;
Weinshenker, BG ;
Antel, JP ;
Confavreux, C ;
Ellison, GW ;
Lublin, F ;
Miller, AE ;
Rao, SM ;
Reingold, S ;
Thompson, A ;
Willoughby, E .
BRAIN, 1999, 122 :871-882
[3]   Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials [J].
Goodkin, DE ;
Priore, RL ;
Wende, KE ;
Campion, M ;
Bourdette, DN ;
Herndon, RM ;
Fischer, JS ;
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Richert, JR ;
Salazar, AM ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Pullicino, PM ;
Scherokman, BJ ;
Weinstock-Guttman, B ;
Whitham, RH .
MULTIPLE SCLEROSIS, 1998, 4 (06) :480-486
[4]   Recommendations from the national multiple sclerosis society clinical outcomes assessment task force [J].
Rudick, R ;
Antel, J ;
Confavreux, C ;
Cutter, G ;
Ellison, G ;
Fischer, J ;
Lublin, F ;
Miller, A ;
Petkau, J ;
Rao, S ;
Reingold, S ;
Syndulko, K ;
Thompson, A ;
Wallenberg, J ;
Weinshenker, B ;
Willoughby, E .
ANNALS OF NEUROLOGY, 1997, 42 (03) :379-382
[5]   The measurement of ambulatory impairment in multiple sclerosis [J].
Schwid, SR ;
Goodman, AD ;
Mattson, DH ;
Mihai, C ;
Donohoe, KM ;
Petrie, MD ;
Scheid, EA ;
Dudman, JT ;
McDermott, MP .
NEUROLOGY, 1997, 49 (05) :1419-1424
[6]  
Schwid SR, 1999, NEUROLOGY, V52, pA549